{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Age, BMI, &amp; TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial &amp; Tirzepatide.","description":" In this week\u2019s View, Dr. Eagle\u202flooks&amp;nbsp;at&amp;nbsp;age,&amp;nbsp;body mass index (BMI), and&amp;nbsp;cardiovascular&amp;nbsp;outcomes after&amp;nbsp;transcatheter aortic valve replacement&amp;nbsp;(TAVR). He&amp;nbsp;follows&amp;nbsp;this with&amp;nbsp;an&amp;nbsp;examination&amp;nbsp;of&amp;nbsp;a new&amp;nbsp;consensus statement about enhanced radiation protection in&amp;nbsp;cath&amp;nbsp;labs,&amp;nbsp;then&amp;nbsp;offers&amp;nbsp;a&amp;nbsp;perspective on particulate matter in the environment and&amp;nbsp;increased&amp;nbsp;coronary&amp;nbsp;heart disease&amp;nbsp;risk.&amp;nbsp;Finally,\u202fDr. Eagle&amp;nbsp;provides&amp;nbsp;an analysis of the SUMMIT Trial, showing the benefit of tirzepatide&amp;nbsp;for&amp;nbsp;heart failure with preserved ejection fraction (HFpEF)&amp;nbsp;both in women&amp;nbsp;and&amp;nbsp;men.&amp;nbsp;&amp;nbsp;   Subscribe to Eagle\u2019s Eye View\u202f\u202f&amp;nbsp;  ","author_name":"Eagle's Eye View: Your Weekly CV Update From ACC.org","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42171155\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/204343370"}